Despite their potential to change the face of medicine, reducing long-term medical costs and curing diseases, innovations in cell and gene therapy face regulatory issues, along with the need for long-term studies, before market acceptance can be achieved.
Research in this important field is undergoing rapid growth. However, due to the significant costs and timescales involved in gaining approval, effective IP strategies must be established to protect investment and maintain market position.
Working across academic research institutes, SMEs and large multinationals, HGF’s specialist cell and gene therapy attorneys tap into their vast experience to develop robust and tailored IP strategies for their clients in this field. The team has extensive experience in helping organisations protect and exploit their IP and assess their freedom to operate.
HGF is a silver sponsor of LSPN Europe 2022 on 29th November in London. This event will explore some of the biggest challenges facing the Life Sciences Patent Community right now …Event details
Case study – alt fat innovation Many companies and investors are aware of the importance of identifying and protecting their innovations, and in particular of the importance of obtaining patents …Read article
HGF is a gold sponsor at the BioCap Conference 2022. The conference will be held on Thursday 22 September at the Alderley Park Conference Centre. It connects life sciences businesses, …Event details
Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …Read article
After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …Event details
HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …Event details
HGF Partner and Patent Attorney Craig Thomson and Patent Director Dr Jennifer Bailey write an article for The Microbiome Times on ELIGO v SNIPR: a reflection on IP strategies in …Read article
One of the most often asked questions of patent attorneys is “when should we file?” Both timing and content of a first filing should be important strategic decisions. This is …Read article